---
title: "Kodiak Sciences Inc. (KOD.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/KOD.US/overview.md"
symbol: "KOD.US"
name: "Kodiak Sciences Inc."
parent: "https://longbridge.com/zh-HK/quote/KOD.US.md"
datetime: "2026-04-06T13:15:02.108Z"
locales:
  - [en](https://longbridge.com/en/quote/KOD.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KOD.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KOD.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/KOD.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/KOD.US/overview.md)


# Kodiak Sciences Inc. (KOD.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Biotechnology |
| 交易所 | US Market |
| 地址 | 1250 Page Mill Road, Palo Alto, California, United States |
| 官網 | [kodiak.com](https://kodiak.com) |

## 公司簡介

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Victor Perlroth | Co-Founder, Chairman, CEO & President |
| John A. Borgeson | Executive VP, CFO & Secretary |
| Dolly S. Chang | Chief Scientific Officer |
| Hong Liang | Senior Vice President of Development |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing |
| Felix James Baker | Independent Director |
| Robert A. Profusek | Lead Independent Director |
| Charles A. Bancroft | Independent Director |
| Bassil I. Dahiyat | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Baker Bros. Advisors LP | 32.27% | 2025-12-31 |
| BlackRock, Inc. | 6.41% | 2025-12-31 |
| Victor Perlroth | 3.88% | 2026-03-25 |
| The Vanguard Group, Inc. | 3.75% | 2025-12-31 |
| Point72 Asset Management, L.P. | 3.51% | 2025-12-31 |
| Braidwell LP | 3.36% | 2025-12-31 |
| State Street Global Advisors, Inc. | 2.81% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 2.56% | 2025-12-31 |
| RTW Investments, LP | 2.41% | 2025-12-31 |
| TCG Crossover Management, LLC | 2.34% | 2025-12-31 |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**